A Phase 1 Pharmacokinetic Study of Intravenous NTM-001 in Healthy Chinese Subjects
Status:
Not yet recruiting
Trial end date:
2022-07-04
Target enrollment:
Participant gender:
Summary
This will be a single center, open-label phase 1 study in healthy Chinese subjects. A total
of up to 16 subjects may be enrolled to achieve a total target of 12 evaluable subjects. A
full dose for NTM-001 will be defined as a 12.5 mg IV Loading Dose + 24-hour IV infusion (3.5
mg/hour).